Khurshid S, Choi SH, Weng LC, Wang EY, Trinquart L, Benjamin EJ, et al. Frequency of cardiac rhythm abnormalities in a half million adults. Circ Arrhythm Electrophysiol. 2018;11(7):e006273. https://doi.org/10.1161/CIRCEP.118.006273.
Article PubMed PubMed Central Google Scholar
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22(8):983–8. https://doi.org/10.1161/01.STR.22.8.983.
CAS Article PubMed Google Scholar
Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ). Orale Antikoagulation bei nicht valvulärem Vorhofflimmern Empfehlungen zum Einsatz der direkten oralen Antikoagulanzien Dabigatran, Apixaban, Edoxaban und Rivaroxaban 2019. Available from: https://www.akdae.de/Arzneimitteltherapie/LF/PDF/OAKVHF.pdf.
Hein L, Wille H. Antithrombotika und Antihämorrhagika. In: Schwabe U, Paffrath D, Ludwig W-D, Klauber J, editors. Arzneiverordnungs-Report 2019. Berlin, Heidelberg: Springer Berlin Heidelberg; 2019. p. 531–55.
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92. https://doi.org/10.1056/NEJMoa1107039.
CAS Article PubMed Google Scholar
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51. https://doi.org/10.1056/NEJMoa0905561.
CAS Article PubMed Google Scholar
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104. https://doi.org/10.1056/NEJMoa1310907.
CAS Article PubMed Google Scholar
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91. https://doi.org/10.1056/NEJMoa1009638.
CAS Article PubMed Google Scholar
European Medicines Agency. Eliquis: EPAR - Product Information 2011. Available from: https://www.ema.europa.eu/en/documents/product-information/eliquis-epar-product-information_en.pdf.
European Medicines Agency. Xarelto : EPAR - Product Information: 2009. Available from: https://www.ema.europa.eu/en/documents/product-information/xarelto-epar-product-information_en.pdf.
European Medicines Agency. Lixiana : EPAR - Product Information: 2015. Available from: https://www.ema.europa.eu/en/documents/product-information/lixiana-epar-product-information_en.pdf.
European Medicines Agency. Pradaxa : EPAR - Product Information: 2009. Available from: https://www.ema.europa.eu/en/documents/product-information/pradaxa-epar-product-information_en.pdf.
Steinberg BA, Shrader P, Pieper K, Thomas L, Allen LA, Ansell J, et al. Frequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants: results from ORBIT-AF II (the outcomes registry for better informed treatment of atrial fibrillation II). J Am Heart Assoc. 2018;7(4):e007633. https://doi.org/10.1161/JAHA.117.007633.
CAS Article PubMed PubMed Central Google Scholar
Hohnloser SH, Basic E, Hohmann C, Nabauer M. Effectiveness and safety of non-vitamin K Oral anticoagulants in comparison to Phenprocoumon: data from 61,000 patients with atrial fibrillation. Thromb Haemost. 2018;118(3):526–38. https://doi.org/10.1160/TH17-10-0733.
Mueller S, Groth A, Spitzer SG, Schramm A, Pfaff A, Maywald U. Real-world effectiveness and safety of oral anticoagulation strategies in atrial fibrillation: a cohort study based on a German claims dataset. Pragmat Obs Res. 2018;9:1–10. https://doi.org/10.2147/POR.S156521.
Article PubMed PubMed Central Google Scholar
Zeymer U, Lober C, Wolf A, Richard F, Schäfer H, Taggeselle J, et al. Use, persistence, efficacy, and safety of Apixaban in patients with non-Valvular atrial fibrillation in unselected patients in Germany. Results of the prospective Apixaban in atrial fibrillation (APAF) registry. Cardiol Ther. 2020;9(2):467–78. https://doi.org/10.1007/s40119-020-00188-1.
Article PubMed PubMed Central Google Scholar
Staerk L, Gerds TA, Lip GYH, Ozenne B, Bonde AN, Lamberts M, et al. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study. J Intern Med. 2018;283(1):45–55. https://doi.org/10.1111/joim.12683.
CAS Article PubMed Google Scholar
Miyazaki M, Matsuo K, Uchiyama M, Nakamura Y, Sakamoto Y, Misaki M, et al. Inappropriate direct oral anticoagulant dosing in atrial fibrillation patients is associated with prescriptions for outpatients rather than inpatients: a single-center retrospective cohort study. J Pharm Health Care Sci. 2020;6:2. https://doi.org/10.1186/s40780-020-0157-z.
Article PubMed PubMed Central Google Scholar
Nielsen PB, Skjoth F, Sogaard M, Kjaeldgaard JN, Lip GY, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2017;356:j510. https://doi.org/10.1136/bmj.j510.
Article PubMed PubMed Central Google Scholar
Beinema M, Brouwers JR, Schalekamp T, Wilffert B. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost. 2008;100(6):1052–7. https://doi.org/10.1160/TH08-04-0116.
CAS Article PubMed Google Scholar
Prochaska JH, Göbel S, Keller K, Coldewey M, Ullmann A, Lamparter H, et al. Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service–results from the prospective, multi-center, observational cohort study thrombEVAL. BMC Med. 2015;13:14. https://doi.org/10.1186/s12916-015-0268-9.
CAS Article PubMed PubMed Central Google Scholar
Le Heuzey JY, Ammentorp B, Darius H, De Caterina R, Schilling RJ, Schmitt J, et al. Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. Thromb Haemost. 2014;111(5):833–41. https://doi.org/10.1160/TH13-12-1007.
CAS Article PubMed Google Scholar
Swart E, Gothe H, Geyer S, Jaunzeme J, Maier B, Grobe T, et al. Gute Praxis Sekundärdatenanalyse (GPS): Leitlinien und Empfehlungen. Das Gesundheitswesen. 2015;77(2):120–6. https://doi.org/10.1055/s-0034-1396815.
CAS Article PubMed Google Scholar
Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The REporting of studies conducted using observational routinely-collected health data (RECORD) statement. PLoS Med. 2015;12(10):e1001885. https://doi.org/10.1371/journal.pmed.1001885.
Article PubMed PubMed Central Google Scholar
Schulman S, Kearon C, Subcommittee on control of anticoagulation of the S, standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–4. https://doi.org/10.1111/j.1538-7836.2005.01204.x.
CAS Article PubMed Google Scholar
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83. https://doi.org/10.1016/0021-9681(87)90171-8.
CAS Article PubMed Google Scholar
Yao X, Gersh BJ, Sangaralingham LR, Kent DM, Shah ND, Abraham NS, et al. Comparison of the CHA2DS2-VASc, CHADS2, HAS-BLED, ORBIT, and ATRIA Risk Scores in Predicting Non–Vitamin K Antagonist Oral Anticoagulants-Associated Bleeding in Patients With Atrial Fibrillation. Am J Cardiol. 2017;120(9):1549–56. https://doi.org/10.1016/j.amjcard.2017.07.051.
CAS Article PubMed Google Scholar
R Core Team. R: A language and environment for statistical computing. R Foundation for statistical computing Vienna, Austria: 2021. Available from: https://www.R-project.org/.
Ho D, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw. 2011;42(8):1–28. https://doi.org/10.18637/jss.v042.i08.
Therneau TM, Grambsch PM. A package for survival analysis in R: 2020. Available from: https://CRAN.R-project.org/package=survival.
Camm AJ, Cools F, Virdone S, Bassand JP, Fitzmaurice DA, Arthur Fox KA, et al. Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct Oral anticoagulants. J Am Coll Cardiol. 2020;76(12):1425–36. https://doi.org/10.1016/j.jacc.2020.07.045.
CAS Article PubMed Google Scholar
Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, et al. Off-label dosing of non-vitamin K antagonist Oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am Coll Cardiol. 2016;68(24):2597–604. https://doi.org/10.1016/j.jacc.2016.09.966.
CAS Article PubMed Google Scholar
Kang F, Ma Y, Cai A, Cheng X, Liu P, Kuang J, et al. Meta-analysis evaluating the efficacy and safety of low-intensity warfarin for patients >65 years of age with non-Valvular atrial fibrillation. Am J Cardiol. 2021;142:74–82. https://doi.org/10.1016/j.amjcard.2020.12.001.
Lee KN, Choi JI, Boo KY, Kim DY, Kim YG, Oh SK, et al. Effectiveness and safety of off-label dosing of non-vitamin K antagonist anticoagulant for atrial fibrillation in Asian patients. Sci Rep. 2020;10(1):1801. https://doi.org/10.1038/s41598-020-58665-5.
CAS Article PubMed PubMed Central Google Scholar
Reinecke H, Jürgensmeyer S, Engelbertz C, Gerss J, Kirchhof P, Breithardt G, et al. Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study. BMJ Open. 2018;8(9):e022690. https://doi.org/10.1136/bmjopen-2018-022690.
Article PubMed PubMed Central Google Scholar
Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394(10206):1335–43. https://doi.org/10.1016/S0140-6736(19)31872-0.
CAS Article PubMed Google Scholar
Riesinger L, Strobl C, Leistner DM, Gori T, Akin I, Mehr M, et al. Apixaban versus PhenpRocoumon: Oral AntiCoagulation plus antiplatelet tHerapy in patients with acute coronary syndrome and atrial fibrillation (APPROACH-ACS-AF): rationale and design of the prospective randomized parallel-group, open-label, blinded-endpoint, superiority, multicenter-trial of a triple therapy versus a dual therapy in patients with atrial fibrillation and acute coronary syndrome undergoing coronary stenting. Int J Cardiol Heart Vasc. 2021;35:100810. https://doi.org/10.1016/j.ijcha.2021.100810.
留言 (0)